Compare GAIA & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | QTTB |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.9M | 80.0M |
| IPO Year | 1999 | 2018 |
| Metric | GAIA | QTTB |
|---|---|---|
| Price | $2.78 | $5.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.50 | ★ $13.00 |
| AVG Volume (30 Days) | 68.5K | ★ 348.9K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.18 | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | $4,500,000.00 | ★ $53,737,000.00 |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $12.04 | N/A |
| P/E Ratio | ★ N/A | $2.03 |
| Revenue Growth | ★ 12.50 | N/A |
| 52 Week Low | $2.45 | $1.40 |
| 52 Week High | $6.39 | $8.05 |
| Indicator | GAIA | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 42.51 |
| Support Level | $2.45 | $3.26 |
| Resistance Level | $3.46 | $6.37 |
| Average True Range (ATR) | 0.13 | 0.84 |
| MACD | 0.01 | -0.27 |
| Stochastic Oscillator | 47.63 | 7.78 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).